Episenta licensed for bipolar disorder

Episenta offers new option in bipolar disorder
Episenta offers new option in bipolar disorder

Episenta (sodium valproate) can now be prescribed to treat manic episodes in bipolar disorder when lithium is contraindicated or not tolerated. Treatment can be continued after the manic episode in patients who respond. Available as prolonged-release capsules and granules and as a solution for injection, Episenta was previously licensed only as an anti-epileptic.

The recommended initial dose for the new indication is 750mg daily in one or two divided doses. The dose should be increased as rapidly as possible to achieve the lowest effective dose, which is usually between 1g and 2g daily.

NICE recommends valproate as a first-line treatment for bipolar disorder. Depakote (valproic acid) is also licensed for bipolar mania in patients who cannot take lithium.  

View Episenta drug record

Further Information: Beacon Pharmaceuticals

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Drug shortages - live tracker

Drug shortages - live tracker

Check on the latest drug supply issues with MIMS' shortages...

Novel MS drug gains NICE approval

Novel MS drug gains NICE approval

New NICE guidance recommends ocrelizumab (Ocrevus)...

Emollients, Potential Skin Sensitisers as Ingredients

Emollients, Potential Skin Sensitisers as Ingredients

Potential sensitising agents in emollient preparations.

NICE recommends new triple therapy option for diabetes

NICE recommends new triple therapy option for diabetes

Ertugliflozin (Steglatro) can now be prescribed routinely...